TITLE

Radiopharmaceuticals for Drug Development: United States Regulatory Perspective

AUTHOR(S)
VanBrocklin, Henry F.
PUB. DATE
January 2008
SOURCE
Current Radiopharmaceuticals;Jan2008, Vol. 1 Issue 1, p2
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Imaging with radiopharmaceuticals is playing an increasingly important role in the development of new drugs. At nearly every step of the process imaging may be used to assess the status of the candidate drugs and assist in determining the lead molecules for further evaluation. Incorporating imaging studies into the paradigm may ameliorate the temporal and economic cost of drug development. Since 1975 radiopharmaceuticals have been regulated as drugs and all human studies must be carried out under an investigational new drug (IND) or radioactive drug research committee (RDRC) protocol. The FDA released the exploratory IND guidance in 2006 to highlight the flexibility in the IND process while trying to stimulate new drug entry into the approval pipeline. The exploratory IND also provides a lower threshold for radiopharmaceutical and candidate drug first in human studies, using the microdosing concept, that may not be conducted under an RDRC protocol. The RDRC mechanism permits the basic research studies with limited dose and numbers of subjects. The RDRC regulations are 30 years old and the full IND process remains burdensome for radiopharmaceutical development. Therefore, it is essential that the regulatory framework permit the approval of radiopharmaceuticals for use in humans that is commensurate with the safety and applications of the probes.
ACCESSION #
62246039

 

Related Articles

  • Regulatory Update. Holmes, Malcolm // GMP Review;Apr2015, Vol. 14 Issue 1, p14 

    The article presents updates on developments in the regulation of the pharmaceutical industry. These include the revised guideline that will clarify to what extent Q9 and Q10 should be followed in the design and implementation of facilities, equipment and processes for the manufacture of sterile...

  • Pathway for Approval of a Gene Therapy Orphan Product: Treading New Ground. Byrne, Barry J // Molecular Therapy;Aug2013, Vol. 21 Issue 8, p1465 

    The author reflects on the approval of a gene therapy orphan product by the U.S. Food and Drug Administration (FDA). He discusses the Food and Drug Administration Safety and Innovation Act (FDASIA) as well as the development of innovative medicines. He also tackles impact of the passage of the...

  • Piloting Track-and-Trace Implementation. Celeste, Robert // Pharmaceutical Technology Europe;Nov2015, Vol. 27 Issue 11, p35 

    The article focuses on the U.S. Drug Supply Chain Security Act (DSCSA) whose requirements the pharmaceutical industry has to meet. Pilot programmes are necessary to determine the feasibility of DSCSA compliance. Information flow is critical to meeting DSCSA requirements in addition to product...

  • Policy 101: Collaborative practice empowers pharmacists to practice as providers. WEAVER, KRYSTALYN K. // Pharmacy Today;Oct2014, Vol. 20 Issue 10, p56 

    The article provides an overview of the policies governing collaborative practice agreements (CPAs) between pharmacists and other health care providers in the U.S. State provisions allowing pharmacists to practice as providers under a CPA are highlighted. The need for pharmacists to be involved...

  • A Good Health Policy, But . . . ALLEN B. WEST AND JOHN R. GRAHAM // Investors Business Daily;7/7/2015, pA13 

    The authors discuss the 21st Century Cures Act and its implication to the pharmaceutical industry in the U.S. as of 2015. They believe that the legislative bill can help address the issues in pharmaceutical innovation, but they are critical on the mandatory funding proposal attached on it. They...

  • DRUG PANICS IN THE TWENTY-FIRST CENTURY: ECSTASY, PRESCRIPTION DRUGS, AND THE REFRAMING OF THE WAR ON DRUGS. Ahrens, Deborah // Albany Government Law Review;2013, Vol. 6 Issue 2, p396 

    In this article, the author presents his views on the drug policy meant for the regulation of drug use in the United States. Topics discussed include epidemic of Ecstasy in the beginning, impact of the epidemic of prescription drug abuse on the physical as well as psychological conditions and...

  • "War on Drugs": How Will Domestic Legalization Affect International Conflict? FINKELMAN, PAUL // Brown Journal of World Affairs;Fall/Winter2013, Vol. 20 Issue 1, p245 

    An interview with author and professor Paul Finkelman is presented. Topics discussed include the implication of drug domestic legalization for international conflict in the U.S, the link of drug laws and regulation for U.S. foreign relations, and the possible benefits of decriminalization of...

  • Speedy delivery: Bringing generics to market faster. MONKS, RICHARD // Drug Store News;10/20/2014, Vol. 36 Issue 10, p46 

    The article reports regulatory developments in the pharmaceutical sector in the U.S. as of late October 2014, particularly involving generic drugs. It cites the efforts by the Food and Drug Administration (FDA) and the Generic Pharmaceutical Association (GPhA) in finding ways to facilitate the...

  • The Ban on "Off-Label" Pharmaceutical Promotion: Constitutionally Permissible Prophylaxis Against False or Misleading Commercial Speech? Greenwood, Kate // American Journal of Law & Medicine;2011, Vol. 37 Issue 2/3, p278 

    Critics of the Food & Drug Administration's ban on off-label promotion often claim that it violates the First Amendment because it suppresses pharmaceutical manufacturers' truthful speech about their legal-and beneficial-products. Characterizing the ban on off-label promotion in this way has...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics